相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
Jean-Luc Van Laethem et al.
TARGETED ONCOLOGY (2017)
Epigenetics of epithelial-to-mesenchymal transition in pancreatic carcinoma
Max M. Traeger et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
Junyu Long et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Clinical trials of CAR-T cells in China
Bingshan Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Recent advances of bispecific antibodies in solid tumors
Shengnan Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Shengnan Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al.
LANCET (2017)
EMT and inflammation: inseparable actors of cancer progression
Meggy Suarez-Carmona et al.
MOLECULAR ONCOLOGY (2017)
Pancreatic cancer heterogeneity and response to Mek inhibition
K. Pedersen et al.
ONCOGENE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma
Hua-Xiang Xu et al.
SURGERY (2017)
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy SWOG S1115 Study Randomized Clinical Trial
Vincent Chung et al.
JAMA ONCOLOGY (2017)
A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
Keiichi Okano et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer
Guopei Luo et al.
ANNALS OF SURGERY (2017)
ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer
Chen Liang et al.
CANCER LETTERS (2017)
Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes
Kelly E. Craven et al.
ONCOTARGET (2016)
Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells
Sivapriya Ponnurangam et al.
ONCOTARGET (2016)
Locally Advanced Pancreatic Cancer Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients
Thilo Hackert et al.
ANNALS OF SURGERY (2016)
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer (vol 115, pg 789, 2016)
Angus G. Dalgleish et al.
BRITISH JOURNAL OF CANCER (2016)
Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in a TNFRSFIOA-related manner
Shangyou Zheng et al.
CANCER LETTERS (2016)
Key role of pancreatic stellate cells in pancreatic cancer
Srinivasa P. Pothula et al.
CANCER LETTERS (2016)
Current progress in immunotherapy for pancreatic cancer
Kelly Foley et al.
CANCER LETTERS (2016)
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
Katsuhiko Uesaka et al.
LANCET (2016)
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam et al.
LANCET (2016)
A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns
Faiyaz Notta et al.
NATURE (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
The effect of PI3K inhibitor LY294002 and gemcitabine hydrochloride combined with ionizing radiation on the formation of vasculogenic mimicry of Panc-1 cells in vitro and in vivo
R. Bai et al.
NEOPLASMA (2016)
Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer
Zheng Wu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies
Xuequn Ren et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
Wan-Ching Yen et al.
CLINICAL CANCER RESEARCH (2015)
A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer
L. Bergmann et al.
EUROPEAN JOURNAL OF CANCER (2015)
Malignant potential in pancreatic neoplasm; new insights provided by circulating miR-223 in plasma
Shuhei Komatsu et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Analysis of the immunomodulatory properties of two heat-killed mycobacterial preparations in a human whole blood model
Samer Bazzi et al.
IMMUNOBIOLOGY (2015)
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
Mitesh J. Borad et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
Herbert I. Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Daniel V. T. Catenacci et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Alternative molecular formats and therapeutic applications for bispecific antibodies
Christoph Spiess et al.
MOLECULAR IMMUNOLOGY (2015)
Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma
Raphael Marechal et al.
CLINICAL CANCER RESEARCH (2015)
A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer
Liang Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer
Henriette Golcher et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2015)
JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells
Shuhei Suzuki et al.
ONCOTARGET (2015)
Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
Claudia C. S. Chini et al.
CLINICAL CANCER RESEARCH (2014)
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Jeffrey R. Infante et al.
EUROPEAN JOURNAL OF CANCER (2014)
Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection
Hua-Xiang Xu et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma
Ana De Jesus-Acosta et al.
INVESTIGATIONAL NEW DRUGS (2014)
MicroRNA Biomarkers in Whole Blood for Detection of Pancreatic Cancer
Nicolai A. Schultz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
Lee M. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Synergistic Activities of MET/RON Inhibitor BMS-777607 and mTOR Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells
Jun-Ying Zeng et al.
MOLECULAR CANCER THERAPEUTICS (2014)
The immune network in pancreatic cancer development and progression
S. M. Woermann et al.
ONCOGENE (2014)
Dosage-Dependent Regulation of Pancreatic Cancer Growth and Angiogenesis by Hedgehog Signaling
Esha Mathew et al.
CELL REPORTS (2014)
Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
Eric R. Lutz et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model
Q. L. Hu et al.
BIOMATERIALS (2013)
A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
Jordan Berlin et al.
CLINICAL CANCER RESEARCH (2013)
Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)
Andrew B. Nixon et al.
CLINICAL CANCER RESEARCH (2013)
Indometacin Ameliorates High Glucose-Induced Proliferation and Invasion Via Modulation of E-Cadherin in Pancreatic Cancer Cells
Liang Han et al.
CURRENT MEDICINAL CHEMISTRY (2013)
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
Philippe Rougier et al.
EUROPEAN JOURNAL OF CANCER (2013)
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study
Jeffrey M. Hardacre et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2013)
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
Dung T. Le et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Targeting miR-21 for the Therapy of Pancreatic Cancer
Flavie Sicard et al.
MOLECULAR THERAPY (2013)
Prognostic Impact of Hyaluronan and Its Regulators in Pancreatic Ductal Adenocarcinoma
Xiao-Bo Cheng et al.
PLOS ONE (2013)
Notch inhibitors for cancer treatment
Ingrid Espinoza et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
Vikash P. Chauhan et al.
NATURE COMMUNICATIONS (2013)
The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis
Qing Chang et al.
NEOPLASIA (2013)
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
A. Goncalves et al.
ANNALS OF ONCOLOGY (2012)
EMT and Dissemination Precede Pancreatic Tumor Formation
Andrew D. Rhim et al.
CELL (2012)
EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells
Michele Cioffi et al.
CLINICAL CANCER RESEARCH (2012)
Conceptual Framework for Cutting the Pancreatic Cancer Fuel Supply
Anne Le et al.
CLINICAL CANCER RESEARCH (2012)
Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo
Hiroshi Urakawa et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor
Evripidis Lanitis et al.
MOLECULAR THERAPY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
microRNA signature for human pancreatic cancer invasion and metastasis (Review)
He Cheng et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2012)
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Stefan Heinrich et al.
BMC CANCER (2011)
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models
Georg Feldmann et al.
CANCER BIOLOGY & THERAPY (2011)
STAT3 Plays a Critical Role in KRAS-Induced Pancreatic Tumorigenesis
Ryan B. Corcoran et al.
CANCER RESEARCH (2011)
MicroRNA-10b Expression Correlates with Response to Neoadjuvant Therapy and Survival in Pancreatic Ductal Adenocarcinoma
Meir Preis et al.
CLINICAL CANCER RESEARCH (2011)
Environment, inflammation, and cancer
Pasquale Sansone et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2011)
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy
Carlos A. Ramos et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Pancreatic cancers require autophagy for tumor growth
Shenghong Yang et al.
GENES & DEVELOPMENT (2011)
被撤回的出版物: Over-Expression of FoxM1 Leads to Epithelial-Mesenchymal Transition and Cancer Stem Cell Phenotype in Pancreatic Cancer Cells (Retracted article. See vol. 117, pg. 1963, 2016)
Bin Bao et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2011)
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
Hedy L. Kindler et al.
LANCET ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors
Benjamin Diop-Frimpong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Otto Warburg's contributions to current concepts of cancer metabolism
Willem H. Koppenol et al.
NATURE REVIEWS CANCER (2011)
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial
John P. Neoptolemos et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Hyaluronan Stabilizes Focal Adhesions, Filopodia, and the Proliferative Phenotype in Esophageal Squamous Carcinoma Cells
Soeren Twarock et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy Lee Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205
Philip A. Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma
Zeshaan A. Rasheed et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
Sonja Gillen et al.
PLOS MEDICINE (2010)
A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
Chigusa Morizane et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
Thiruvengadam Arumugam et al.
CANCER RESEARCH (2009)
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
Cornelia Haas et al.
IMMUNOBIOLOGY (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2
Manav Korpal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head
Gauri R. Varadhachary et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head
Douglas B. Evans et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells
Michael Sun et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer
Patrick C. Hermann et al.
CELL STEM CELL (2007)
K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling
Paul M. Campbell et al.
CANCER RESEARCH (2007)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study
S. L. Bernhardt et al.
BRITISH JOURNAL OF CANCER (2006)
Genetics and biology of pancreatic ductal adenocarcinoma
Aram F. Hezel et al.
GENES & DEVELOPMENT (2006)
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
E Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer
D Azria et al.
BRITISH JOURNAL OF CANCER (2003)
Hyaluronan activates cell motility of v-Src-transformed cells via Ras-mitogen-activated protein kinase and phosphoinositide 3-kinase-Akt in a tumor-specific manner
Y Sohara et al.
MOLECULAR BIOLOGY OF THE CELL (2001)
Janus kinases: components of multiple signaling pathways
SG Rane et al.
ONCOGENE (2000)
分享论文
